论文信息 - Reactivation of Tuberculosis in Patients with Ankylosing Spondylitis on Tofacitinib Therapy - 字舞流文

Reactivation of Tuberculosis in Patients with Ankylosing Spondylitis on Tofacitinib Therapy

D. Kumar | Harsimran Kaur | Parminderjit Singh | Manavdeep Kaur

[1] P. Moog,et al. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies , 2020, Frontiers in Immunology.

[2] J. Gómez-Reino,et al. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. , 2014, Rheumatology.

[3] D. Goletti,et al. Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance , 2014, The Journal of Rheumatology. Supplement.

[4] D. Goletti,et al. Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor-α (TNF-α) Targeted Biologics and Recently Licensed TNF-α Inhibitors: Data from Clinical Trials and National Registries , 2014, The Journal of Rheumatology. Supplement.